Key result
Omega-3 fatty acid supplementation significantly reduced serum triglyceride (SMD -0.61), low-density lipoprotein (SMD -0.35), and C-reactive protein (SMD -0.56) levels in patients with end-stage renal disease.
Why the study?
Does omega-3 fatty acid supplementation improve serum lipids and vascular inflammation markers in patients with end-stage renal disease?
Meta-Analysis (n=1,461)
Does omega-3 fatty acid supplementation improve serum lipids and vascular inflammation markers in patients with end-stage renal disease?
Standardized Mean Difference: -0.61 (95% CI -1.01–-0.22)
p-value: p=0.002
Omega-3 fatty acid supplementation in patients with end-stage renal disease significantly reduces serum triglycerides, LDL cholesterol, and CRP levels, though it has no significant effect on other lipids or inflammatory markers.
Supports omega-3 use for lipid and CRP reduction in ESRD; extends meta-analytic evidence to this high-risk population.
Omega-3 fatty acids (O3FAs) are associated with lower cardiovascular disease (CVD) risk in adults. However, this association in patients with end-stage renal disease (ESRD) remains controversial prompting the need for investigation into the role of O3FAs on serum lipids and vascular inflammation markers. The present meta-analysis summarized the effects of O3FA supplementation on serum lipids and vascular inflammatory markers in patients with ESRD. PubMed, EmBase, and the Cochrane Library were searched to identify randomized controlled trials (RCTs) focused on serum lipids and vascular inflammation markers in patients with ESRD. Standard mean differences (SMD) were used to measure the effect of O3FA supplementation on serum lipids and vascular inflammatory markers. The final pooled analysis included 20 RCTs involving 1,461 patients with ESRD. The results indicated that O3FA supplementation reduced TG by 0.61, LDL by 0.35 and CRP by 0.56. However, O3FA had no significant effect on TC, HDL, albumin, hemoglobin, homocysteine, DBP, glucose, lipoprotein(a), and ferritin. O3FA supplementation is associated with lower several serum lipids and vascular inflammation markers in patients with ESRD.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2016) conducted a meta-analysis in End-stage renal disease (ESRD) (n=1,461). Omega-3 fatty acid supplementation vs. Placebo or control was evaluated on Serum triglyceride (TG) levels (SMD -0.61, 95% CI -1.01 to -0.22, p=0.002). Omega-3 fatty acid supplementation significantly reduced serum triglyceride (SMD -0.61), low-density lipoprotein (SMD -0.35), and C-reactive protein (SMD -0.56) levels in patients with end-stage renal disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: